We use Google Analytics to count anonymous page views and understand which content gets read. No ads, no profiles. Decline keeps you on cookieless mode. Details.
CRISPR Therapeutics AG
Health Care · Biotechnology
Structural: $CRSP is the listed pure-play on CRISPR/Cas9 therapeutic editing, with Casgevy now approved in US/EU/UK/Saudi/Bahrain for SCD + TDT - the first-ever CRISPR gene edit medicine. Vertex ($VRTX) owns 60% of Casgevy economics and books revenue; $CRSP recognizes 40% net profit/loss share plus milestones.
9B cash gives multi-year runway through 2027+ at current burn.
(1) Casgevy ramp inflecting - ~50 authorized treatment centers globally, ex-US reimbursement expanding 2026, addressable pop ~32k SCD + ~5k TDT in commercial geos; (2) allogeneic CAR-T (CTX112 in CD19 lymphoma, CTX131 in solid tumors) is the differentiated off-the-shelf bet vs autologous incumbents; (3) in vivo lipid program (CTX310 ANGPTL3, CTX320 LPA) is the platform-validation shot at the $VERV/$NTLA addressable cardiovascular pool; (4) cash + $VRTX cost-share shields dilution risk vs $EDIT/$BEAM/$NTLA.
2M list, 6-12mo cell-collection-to-infusion cycle caps revenue trajectory; (2) base editing ($BEAM, $VERV) and prime editing ($PRME) may obsolete first-gen Cas9 cutting in 5-10yr; (3) CAR-T allogeneic field has serial setbacks (rejection, persistence) and $CRSP competes with $ALLO, $CRBU, $FATE-class peers; (4) single-product commercial concentration - any Casgevy safety signal is binary; (5) cash burn of ~$300M/yr against pre-profit P&L.
Each weekday: the scan's ENTER setups with entry, stop and target, every new ticker teardown, and the bubble shifts that move names like this one. Free. Education, not advice.
No spam. One email per day max. Pro adds Telegram trade alerts and higher AI-assistant limits.
No major news in the last 7 days for CRSP - only listicles and opinion pieces, which we filter out by default. See everything anyway.
Auto-computed retracement of the trailing 52w low-high leg. Recomputed on each refresh; not a curated level.
Auto-computed retracement of the trailing 52w low-high leg. Recomputed on each refresh; not a curated level.
Auto-computed retracement of the trailing 52w low-high leg. Recomputed on each refresh; not a curated level.
Auto-computed retracement of the trailing 52w low-high leg. Recomputed on each refresh; not a curated level.